Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review.
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index; 15 of the 37 sources its claims cite were checked for support.
Abstract
Anti-dsDNA testing shows considerable variation in test specificity, with potential impact on the management of SLE patients. This systematic review identified studies reporting anti-dsDNA test accuracy in SLE. A meta-analysis was conducted to estimate specificity by test method. CLIFT and fluorescence enzyme immunoassay methods are likely to be >= 90% specific. CLIFT specificity was estimated at 98.7% (95% CI 96.7%-99.5%) based on 8 studies/7 tests, while Euroimmun specificity was 97.8% and EliA specificity was 94.7%. Specificities of other quantitative methods were not fully demonstrated to be >= 90%.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 30 studies covering 43 anti-dsDNA tests found considerable variation in specificity for SLE, with some tests likely exceeding 90% specificity and others not demonstrated to do so. The authors conclude that test choice and interpretation should account for method, named test, and the relevance of the control group.
Key findings
- Across 30 studies and 66 result sets for 43 anti-dsDNA tests, some studies reported false-positive rates above 10%: 2 CLIA, 2 NOVA Lite CLIFT, 4 ELISA, 3 Farr-RIA, and 3 MIA studies.
- Pooled specificity estimates were: Euroimmun CLIFT 97.8% (95% CI 96.2%–98.7%), 4 studies; EliA FEIA 94.7% (95% CI 91.7%–96.7%), 6 studies; CLIFT overall 98.7% (95% CI 96.7%–99.5%), 8 studies/7 tests.
- Other estimates were: NOVA Lite CLIFT 96.0% (95% CI 87.2%–98.9%), 5 studies; CLIA 92.3% (95% CI 83.6%–96.6%), 6 studies/4 tests; MIA 89.3% (95% CI 86.1%–91.8%), 4 studies/2 tests; Farr-RIA 93.8% (95% CI 85.4%–97.5%), 11 studies/9 tests; ELISA 93.4% (95% CI 89.9%–95.7%), 15 studies/16 tests.
- FEIA EliA and some CLIFT tests were likely to have >90% specificity and were assessed against relevant disease controls; for other methods, specificity was not fully demonstrated to be >90% and/or control groups included healthy patients, possibly overestimating specificity.
Methods
- Systematic review of MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Database of Abstracts of Reviews of Effects, including cross-sectional or case-control diagnostic accuracy studies published January 2004 to August 2019, with at least 10 patients, an SLE cohort, a non-SLE control group, accepted SLE classification criteria (ACR 1982, ACR 1997, or SLICC 2012), and commercially available anti-dsDNA tests at manufacturer-recommended thresholds.
- Thirty studies were included, yielding 66 sets of results for 43 different anti-dsDNA tests; study quality was assessed with QUADAS-2.
- Specificity was calculated with exact (Clopper-Pearson) 95% CIs, and hierarchical summary ROC meta-analysis was conducted by test method or named test where feasible; when studies reported healthy and diseased controls separately, specificity was based on disease controls only.
Limitations
- The paper states that most included studies were conducted in secondary/tertiary care settings and mostly European countries, which may limit generalization to primary care; the review was not designed to assess sensitivity; and too few data were available for individual tests within CLIA, MIA, Farr-RIA, and ELISA.
- The paper states that 90% of studies used a case-control design, that some studies included healthy controls or non-representative disease controls, and that this may overestimate specificity; one CLIFT NOVA Lite result of 44% was excluded as an outlier.
- The text makes evident potential conflict of interest: several authors report employment, stock ownership, personal fees, or grants from Thermo Fisher Scientific, and the review includes the EliA FEIA test from that company.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 8 Not checked · 92 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Many test methods are available and anti-dsDNA tests, by design, detect different subpopulations of anti-dsDNA with distinct fine specificities (16,20,(22)(23)(24).”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > INTRODUCTION
What the sources say
- Partly supportedcites [16] Arana R, Seligmann M. Antibodies to native and denatured deoxyribonucleic acid in systemic lupus erythematosus. J Clin Invest 1967;46:1867-82. sourceExperimental — accuracy not yet measured
The Discussion reports anti-DNA antibodies with different specificities and shows that complement-fixation and double-diffusion tests reveal different patterns of reactivity with native and denatured DNA. It also cautions that micro-complement fixation reflects only the most concentrated antibody populations. These findings support assay-dependent detection, but the paper does not establish the broader claim that anti-dsDNA test methods are designed to detect distinct subpopulations with distinct fine specificities. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [20] Andrejevic S, Jeremic I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci-Nikolic B. Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. Clin Rheumatol 2013;32:1619-26. source
- Not checked — no full text of the sourcecites [22] Werle E, Blazek M, Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992;1:369-77. source
- Not checked — no full text of the sourcecites [23] Smeenk R, van der Lelij G, Aarden L. Avidity of antibodies to dsDNA: comparison of IFT on Crithidia luciliae, Farr assay, and PEG assay. J Immunol 1982;128 1:73-8. source
- Not checked — no full text of the sourcecites [24] Smeenk RJ, Van Rooijen A, Swaak TJ. Dissociation studies of DNA/anti-DNA complexes in relation to anti-DNA avidity. J Immunol Methods 1988;109:27-35. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The included studies used ACR 1982 (33), ACR 1997 (13), SLICC 2012 (3), or a combination of these classification criteria to define the SLE group.”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > Summary of Study Quality Assessment
What the sources say
- Not checked — no full text of the sourcecites [33] Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. source
- Not checked — no full text of the sourcecites [13] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725. source
- Supportedcites [3] Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677-86. source
The citation is attached to “SLICC 2012,” identifying the classification criteria used by some included studies. The Abstract (Results) sets out the SLICC criteria for SLE classification, and the Discussion describes them as alternative criteria for use in SLE research. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“the assessment of whether studies measured specificity in a relevant disease control group was guided by the derivation and validation cohorts used to develop the 2019 EULAR/ACR classification criteria”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > Relevance of Disease Controls
What the sources say
- Supportedcites [2] Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71: 1400-12. source
The Phase IV: Refinement and validation section describes the derivation and validation cohorts used to develop the criteria. It says their controls had conditions mimicking SLE, providing a relevant disease-control group for the citing authors’ assessment. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“the EULAR/ACR noted that some anti-dsDNA tests used in practice have relatively low specificity (2).”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > IMPACT STATEMENT
What the sources say
- Could not verifycites [2] Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71: 1400-12. sourceExperimental — accuracy not yet measured
The classification-criteria figure lists anti-dsDNA antibodies, but the retrieved passage does not explain its asterisk or discuss the specificity of anti-dsDNA tests. Searches for anti-dsDNA assay specificity and low-specificity tests returned passages about ANA or the specificity of the overall classification criteria, not the claim. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“While the differences in the tests could hamper efforts toward test harmonization in autoimmune diagnostics (72), this is also an opportunity to adopt complimentary diagnostic approaches depending on the setting, such as a combination of a sensitive and a highly specific test (6).”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > DISCUSSION
What the sources say
- Supportedcites [72] Jacobs JFM, Bossuyt X. Standardization and harmonization of autoimmune diagnostics. Clin Chem Lab Med 2018;56:1563-7. source
The section “Detection of autoantibodies: what do we measure?” says that differences between diagnostic methods make standardizing and harmonizing autoimmune diagnostics extremely challenging. It also links differing test characteristics to discrepancies between assays. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
52 more claims · 2 with their cited sources checked
Create a free account to see all 111 claims and to verify the 3 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 23
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Moreover, this result might indicate that CLIFT displays negative results after treatment faster than FEIA, probably owing to its lower sensitivity, as previously reported.12 27”
From Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: Does a gold standard dsDNA assay exist? (2023) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > DISCUSSION
“Some studies report false-positive rates above 10% (out of 30 studies: 2 CLIA, 2 NOVA Lite CLIFT, 4 ELISA, 3 Far-RIA, 3 MIA).”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > Summary of Anti-dsDNA Specificity by Test Method/Named Test
“Three out of the six studies with data for CLIA tests reported a specificity point estimate less than 90%”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > •
“for 3 studies, the disease controls may not be representative of controls in practice.”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > CLIFT (other tests).
“and for two studies, the disease controls may not be representative of controls in practice.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > Summary of Anti-dsDNA Specificity by Test Method/Named Test
“It is noted that 15.1% of control subjects were healthy controls”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > Summary of Anti-dsDNA Specificity by Test Method/Named Test
“• Not demonstrated against relevant disease controls: 11% of control subjects were healthy controls and for 2 studies the disease controls may not be representative of controls in practice”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > •
“0% 91% (95% CI 86%, 96%) study estimate”
§ Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review > MIA.
“One additional study reported data for FIDIS (specificity 91.9%).”
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519 · cited 2×
“The included studies used ACR 1982 (33), ACR 1997 (13), SLICC 2012 (3), or a combination of these classification criteria to define the SLE group.”
BackgroundMethodQUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409 · cited 2×
“The included studies used ACR 1982 (33), ACR 1997 (13), SLICC 2012 (3), or a combination of these classification criteria to define the SLE group.”
BackgroundMethodPetri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322 · cited 3×
“The included studies used ACR 1982 (33), ACR 1997 (13), SLICC 2012 (3), or a combination of these classification criteria to define the SLE group.”
BackgroundMethodTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“1 and 2) with a 95% CI calculated using the exact (Clopper-Pearson) method (35).”
MethodMcInnes, M. D. F., Moher, D., Thombs, B. D., McGrath, T. A., Bossuyt, P. M., and the PRISMA-DTA Group, Clifford, T., Cohen, J. F., Deeks, J. J., Gatsonis, C., et al. (2018) · JAMA · doi:10.1001/jama.2017.19163 · Cited by 3,210 · cited 1×
“The literature search citation flow is reported as per the Preferred Reporting Items for Systematic reviews and Metaanalyses of Diagnostic Test Accuracy studies statement (34) and is provided in Supplemental Fig.”
MethodAringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40930 · Cited by 2,677
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214819 · Cited by 1,612
A hierarchical regression approach to meta‐analysis of diagnostic test accuracy evaluations
Rutter, C. M., & Gatsonis, C. A. (2001) · Statistics in Medicine · doi:10.1002/sim.942 · Cited by 1,505 · cited 1×
“In addition, hierarchical summary ROC (HSROC) curve plots of sensitivity vs specificity (expressed as 1 specificity) were generated after fitting the test count data (36, 37).”
MethodKaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Research works printed but not linked: 4
- Conrad K, Scho ¨ßler W, Hiepe F, Fritzler MJ. Double- stranded DNA (dsDNA) Antibodies. In Autoantibodies in systemic autoimmune diseases. 3rd Ed. Dresden, Germany: PABST; 2015. p. 73-4.
- Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y. Analysing and presenting results. In: Deeks J, Bossuyt P, Gatsonis C, Editors. Handbook for systematic reviews of diagnostic test accuracy version 10. Cochrane: The Cochrane Collaboration; 2010. https://methods. cochrane.org/sdt/handbook-dta-reviews.
- Pluddemann A, Banerjee A, O'Sullivan J; Catalogue of Bias Collaboration. Spectrum bias. In: Catalogue of bias. University of Oxford; 2019. http://www.catalogofbias.org/ biases/selection-bias/.
- Lopez-Hoyos M, Ayerbe I, Martinez-Taboada VM, Bartolome MJ, Blanco R, Lopez-Escribano H, et al. Clinical utility of antibodies to double-stranded DNA by a new immunofluorescence test. Lupus 2004;13: 144-7.
Cited by
Damoiseaux, J. G. M. C., & van Beers, J. J. B. C. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100191 · Cited by 24
Bauer, C.-J., Karakostas, P., Weber, N., Behning, C., Stoffel‐Wagner, B., Brossart, P., Dolscheid‐Pommerich, R., & Schäfer, V. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1305865 · Cited by 21
Regulation of biomarker analysis: what can be translated in the clinic?
Diamantopoulos, M. A., Boti, M. A., Sarri, T., Tounias, G., Psychogyiou, D. D., & Scorilas, A. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2534962 · Cited by 17
Lei, R., Arain, H., Wang, D., Arunachalam, J., Saxena, R., & Mohan, C. (2024) · Biosensors · doi:10.3390/bios14020098 · Cited by 12
“Approximately 60–83% of SLE patients have been found to have detectable levels of anti-dsDNA at some point during their illness [18–20], and the specificity of anti-dsDNA ranges from 88% to 99% depending on the testing method (acceptable by EULAR/ACR standards) used [21–23].”
MethodCarlé, C., Fortenfant, F., Bost, C., Bellière, J., Faguer, S., Chauveau, D., Huart, A., Ribes, D., Alric, L., Pugnet, G., et al. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100274 · Cited by 11
Trujillo Aguilera, A., Bernardo Serrano, R., Navas, A., Alcaide Molina, J., Alvarez Romero, P., & Jurado Roger, A. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000984 · Cited by 6
“12 27 Furthermore, CLIFT only detects specific high-avidity dsDNA autoantibodies, while FEIA detects mainly high-avidity and intermediate-avidity dsDNA autoantibodies.”
BackgroundKısaoğlu, H., Şener, S., Aslan, E., Baba, Ö., Şahin, S., Bilginer, Y., Kasapçopur, Ö., Özen, S., & Kalyoncu, M. (2023) · Rheumatology · doi:10.1093/rheumatology/kead647 · Cited by 6
Cutting edge confusion about cut-off settings in autoimmune diagnostics
Damoiseaux, J. G. M. C., Bontkes, H. J., & Mulder, L. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103650 · Cited by 8
Lan, W., Lu, Q., Jiang, Z., Ma, W., Hou, L., Li, D., Rui, X., & Tang, F. (2026) · iScience · doi:10.1016/j.isci.2026.115738 · Cited by 7
“101,102 Furthermore, the combination of belimumab with traditional induction therapy has been shown to improve the rates of renal response and prevent renal flares in patients with LN. 99 Belimumab is also well-tolerated, with similar frequency of infections and infusion reactions compared to that in the placebo arms.”
InfluentialPapale, M., Paolillo, C., Iafelice, L., Trivisano, T., Netti, G. S., Ranieri, E., & Corso, G. (2026) · Antibodies · doi:10.3390/antib15020023 · Cited by 4
A Rare Case of Antinuclear Antibody (ANA)-Negative Lupus Nephritis
Bakshi, N., Munir, T., Guma, M., et al. (2023) · Cureus · doi:10.7759/cureus.41480 · Cited by 3
Alrashdi, M. N., Alharbi, A. M., Algubllan, L. A., et al. (2024) · Annals of Rheumatology and Autoimmunity · doi:10.4103/ara.ara_6_24 · Cited by 2
Xia, H., Pan, Z., Hong, Y. S., Zhao, Q., & Fan, W. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.02.018 · Cited by 3
Elghali, M., Yosr, B., Syrine, D., Jguirim, M., Sakly, N., & Hammami, S. O. (2025) · Reumatologia/Rheumatology · doi:10.5114/reum/197390 · Cited by 2
Nieto‐Aristizábal, I., España, L. J., Ortega, J., Ruíz-Ordóñez, I., Vivas, Á. J., Castaño, G. L., Castillo, C. M., Bautista-Vargas, M. A., Suárez, A., Cañas, C. A., et al. (2023) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad006 · Cited by 2
Salihin, N. A. N. M., Mohamad, W. M. W., Thaha, U. A. B. M., Nawi, M. A. A., & Rahim, M. J. C. (2025) · International Journal of Orofacial and Health Sciences · doi:10.31436/ijohs.v6i1.338
Elghali, M., Azizi, M., Jguirim, M., Hammami, S. O., & Sakly, N. (2025) · Laboratory Medicine · doi:10.1093/labmed/lmaf002 · Cited by 1
Novel Biomarkers of SLE with Renal and Neuropsychiatry Complications
Nawaz, M., Nazir, H., Arshad, T., et al. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i4.1017
Anti-dsDNA antibodies: bridging the gap between Sjögren’s syndrome and systemic lupus erythematosus
Hajatmand Targhi, F. Z., & Owlia, M. B. (2025) · Rheumatology Research · doi:10.32592/rr.2025.10.2.73
Zhao, Y., Zhan, M., Chen, J.-N., Xu, H., Feng, F., Bai, Z., Wang, F., Cheng, Y., Zhang, X., & Liu, Y. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120662
Chen, Q., Jin, X., Zheng, Q., He, M. Y., Han, L., Yan, J., Zhan, M., Zhang, P., 柯培锋, Wang, J., et al. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.118223 · Cited by 2
Nagant, C., Taghavi, M., Ziani, H. B. K., Ghorra, N., Badot, V., Parmentier, S., & Corazza, F. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70072 · Cited by 1
“5,6 The Farr radioimmunoassay (RIA) has long been considered the gold standard for anti-dsDNA detection because of its high specificity for high-affinity antibodies.”
Cheng, F., Chu, Y., & Xu, S. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.118135
Yang, C., Meng, J., Ding, N., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1841620
Levy, D. M., & Wenderfer, S. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11980-4.00027-1
Systemic LUPUS Erythematosus Detection Using Deep Learning
Prem Vignesh, K., Arun Murugan, S. K., Rohith, J., et al. (2025) · IEEE International Conference on Cybernetics, Cognition and Machine Learning Applications (ICCCMLA) · doi:10.1109/icccmla66092.2025.11580509
The landscape of serum autoantibodies in lupus nephritis
Bruschi, M., Alberici, F., Moroni, G. L., Vaglio, A., Sinico, R. A., Franceschini, F., Fredi, M., Porta, E. L., Calatroni, M., Cavagna, L., et al. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104128
The erosion of seronegative autoimmune diseases through the lens of autoantibodies
Selmi, C., Tonutti, A., Timilsina, S., & Gershwin, M. E. (2026) · The Lancet Rheumatology · doi:10.1016/s2665-9913(26)00145-1
Amin, N., Bari, A., Islam, M. N., Jahan, N., Raju, M. C., Rashid, M. A., Rahman, M. R., Amin, S., & Zahangir, T. I. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_841_2025
Ogrič, M., Čučnik, S., & Lakota, K. (2026) · Diagnostics · doi:10.3390/diagnostics16162612
Metadata
- Authors
- Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J.
- Affiliations
- ICERA Consulting Ltd, Swindon, UK
- Thermo Fisher Scientific (Sweden) (SE)
- Erasmus MC (NL)
- Corresponding author
- Orme, Michelle E
- ORCID
- Schreurs, Marco W J
- Venue
- The Journal of Applied Laboratory Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 221-239
- ISSN
- 2475-7241 (ISSN-L)
- 2576-9456
- OpenAlex
- W4206109719
- Cited by
- 30
- References
- 75
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 3 · 2023: 6
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Applied Laboratory Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- Funders
- Thermo Fisher Scientific
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- anti-dsDNA antibodies, systemic lupus erythematosus, diagnostic specificity, false positives, autoantibody detection, indirect immunofluorescence, fluorescence enzyme immunoassay, chemiluminescence immunoassay, multiplex immunoassay
- MeSH terms
- Autoantibodies, Cross-Sectional Studies, DNA, Fluorescent Antibody Technique, Humans, Lupus Erythematosus, Systemic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.